Invitation til at blive en del af The International Headache Society

The International Headache Society is the world’s leading membership organisation for those with a professional commitment to helping people affected by headache, and collaborates with partner societies such as the World Federation of Neurology.


Our main focus is on educating neurologists worldwide about headache medicine and offering the latest research through our journal, Cephalalgia.

If members of the DNS want to learn about headache medicine they should join IHS – we are pleased to offer free trial membership for all your members until the end of March 2021! Just visit the IHS website (www.ihs-headache.org) and login:

Username: IHStrial

Password: IHStrial2021


If they then want to join IHS they will receive

  • Subscription to the IHS journal, Cephalalgia, print copy or online-only options available and reduced rates for residents and early-career physicians and researchers
  • Download of Cephalalgia apps
  • Reduced submission fees for publishing in the open-access companion journal, Cephalalgia Reports
  • Access to the IHS online learning centre
  • Early access to IHS clinical trial guidelines
  • Reduced registration fees for IHC 2021, Berlin, Germany, September

More information on the IHS website.


The IHS website Online Learning Centre content includes videos, webinars and podcasts on hot headache topics and meeting presentation from associated societies such as the American Headache Society and Migraine Trust International Symposium.


Our bi-ennial congress, IHC 2021 will take place in September 2021, and for the first time we will join with the European Headache Federation for a joint event. The congress will be live streamed to enable virtual participation.

Abstract submission is now open and IHS members receive reduced registration fees for the congress.


Messoud Ashina

IHS President



Neurologiske patienter med særlig øget risiko for alvorligt sygdomsforløb ved COVID-19

Efter rådgivning fra DNS, er der nu nævnt følgende neurologiske patienter i Sundhedsstyrelsens publikation om risikogrupper ved COVID 19.

Tilstande og sygdomme, der medfører øget risiko for alvorligt sygdomsforløb ved COVID-19

  • Apopleksi, særligt ved nylig apopleksi, svær funktionsnedsættelse eller komorbiditet.
  • Degenerative og neuromuskulære sygdomme, der medfører nedsat hostekraft (fx ALS, myasteni)
  • Kroniske neurologiske sygdomme, fx multipel sklerose, epilepsi og voksne med cerebral parese
  • Fremskreden demenssygdom, uanset baggrund for denne

Dette svarer til vaccinations gruppe 10.

En subgruppe af disse patienter har særlig øget risiko svarende til vaccinations gruppe 5.

Her er der tilføjet følgende kriterier:

Med udgangspunkt i patientgrupperne med neurologiske symptomer, som er nævnt i tabellen om personer med øget risiko, kan følgende tilføjes som kriterier for særligt sårbare patienter.

  • Patienter med neurologiske sygdomme med svært nedsat funktionsniveau, motorisk eller kognitivt.
  • Alle ny diagnosticerede patienter med apopleksi eller TCI, som kan vaccineres når deres almentilstand tillader det.